A Merck & Co. unit is using its option to license potential drug candidates against cardiovascular disease from Xenon Pharmaceuticals. The licensing deal springs from a 2009 strategic collaboration.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||